NLTX Insider Trading
Insider Ownership Percentage: 1.58%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Neoleukin Therapeutics Share Price & Price History
Current Price: $18.49
Price Change: ▲ Price Increase of +0.85 (4.82%)
As of 02/23/2026 01:00 AM ET
Neoleukin Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/17/2023 | Bros. Advisors Lp Baker | Director | Buy | 8,347 | $13.80 | $115,188.60 | 280,647 |  |
| 8/15/2023 | Bros. Advisors Lp Baker | Director | Buy | 94,440 | $12.60 | $1,189,944.00 | 262,330 | |
| 8/11/2023 | Sean Michael Smith | CFO | Sell | 66 | $12.40 | $818.40 | 1,081 | |
| 4/3/2023 | Priti Patel | Insider | Sell | 188 | $13.80 | $2,594.40 | 1,865 | |
Neoleukin Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/15/2023 | Redmile Group LLC | 582,443 | $2.30M | 0.1% | -80.0% | 6.619% |  |
| 11/15/2023 | Kynam Capital Management LP | 24,037 | $95K | 0.0% | -80.0% | 0.273% | |
| 11/15/2023 | Adage Capital Partners GP L.L.C. | 310,000 | $1.22M | 0.0% | N/A | 3.523% | |
| 10/23/2023 | BML Capital Management LLC | 98,664 | $0.39M | 0.4% | +315.4% | 1.121% | |
| 7/26/2023 | Privium Fund Management B.V. | 117,200 | $95K | 0.0% | N/A | 0.274% | |
| 5/15/2023 | MYDA Advisors LLC | 40,000 | $28K | 0.0% | N/A | 0.093% | |
| 5/9/2023 | US Bancorp DE | 44,346 | $31K | 0.0% | +111.2% | 0.104% | |
| 11/14/2022 | Point72 Asset Management L.P. | 2,064,222 | $1.32M | 0.0% | +43.6% | 4.848% | |
| 11/1/2022 | Privium Fund Management UK Ltd | 117,200 | $75K | 0.1% | N/A | 0.275% | |
| 8/15/2022 | Opaleye Management Inc. | 610,000 | $0.63M | 0.3% | -22.8% | 1.433% | |
| 8/9/2022 | Pictet Asset Management SA | 781,551 | $0.81M | 0.0% | -69.6% | 1.839% | |
| 8/8/2022 | Simon Quick Advisors LLC | 46,856 | $49K | 0.0% | N/A | 0.110% | |
| 7/27/2022 | Bailard Inc. | 90,100 | $93K | 0.0% | N/A | 0.212% | |
| 7/14/2022 | Adviser Investments LLC | 65,404 | $67K | 0.0% | +39.7% | 0.154% | |
| 5/12/2022 | Gyon Technologies Capital Management LP | 36,803 | $69K | 0.0% | N/A | 0.087% | |
| 5/11/2022 | ACT Capital Management LLC | 199,000 | $0.37M | 0.4% | -6.4% | 0.468% | |
| 5/4/2022 | Adviser Investments LLC | 46,817 | $88K | 0.0% | +347.6% | 0.110% | |
| 5/2/2022 | Allspring Global Investments Holdings LLC | 45,709 | $85K | 0.0% | N/A | 0.108% | |
| 2/14/2022 | PDT Partners LLC | 39,462 | $0.19M | 0.0% | +90.0% | 0.093% | |
| 2/14/2022 | Redmile Group LLC | 3,490,835 | $16.83M | 0.4% | -0.5% | 8.228% | |
| 2/14/2022 | Point72 Asset Management L.P. | 1,010,790 | $4.87M | 0.0% | +1.1% | 2.382% | |
| 2/14/2022 | GSA Capital Partners LLP | 130,899 | $0.63M | 0.1% | +73.6% | 0.309% | |
| 2/11/2022 | Renaissance Technologies LLC | 843,612 | $4.07M | 0.0% | +11.5% | 1.988% | |
| 2/10/2022 | Pictet Asset Management SA | 2,574,289 | $12.41M | 0.0% | -3.4% | 6.067% | |
| 2/10/2022 | Acadian Asset Management LLC | 23,405 | $0.11M | 0.0% | N/A | 0.055% | |
| 2/8/2022 | Northern Trust Corp | 326,497 | $1.57M | 0.0% | -7.1% | 0.770% | |
| 2/3/2022 | Los Angeles Capital Management LLC | 51,453 | $0.25M | 0.0% | +20.7% | 0.121% | |
| 2/3/2022 | ACT Capital Management LLC | 212,500 | $1.02M | 0.7% | -11.1% | 0.501% | |
| 2/2/2022 | New York State Common Retirement Fund | 14,396 | $69K | 0.0% | -57.2% | 0.034% | |
| 1/31/2022 | Adviser Investments LLC | 10,460 | $50K | 0.0% | N/A | 0.025% | |
| 1/21/2022 | Kestra Private Wealth Services LLC | 12,000 | $58K | 0.0% | N/A | 0.028% | |
| 1/21/2022 | Pinnacle Wealth Planning Services Inc. | 14,303 | $69K | 0.0% | N/A | 0.034% | |
| 11/22/2021 | EcoR1 Capital LLC | 860,619 | $6.22M | 0.2% | -63.5% | 2.028% | |
| 11/16/2021 | Two Sigma Advisers LP | 174,600 | $1.26M | 0.0% | +192.5% | 0.412% | |
| 11/16/2021 | Two Sigma Investments LP | 120,212 | $0.87M | 0.0% | +207.5% | 0.283% | |
| 11/16/2021 | Metropolitan Life Insurance Co NY | 4,698 | $34K | 0.0% | -52.4% | 0.011% | |
| 11/15/2021 | Marshall Wace LLP | 19,421 | $0.14M | 0.0% | N/A | 0.046% | |
| 11/12/2021 | The Manufacturers Life Insurance Company | 11,580 | $84K | 0.0% | -45.8% | 0.027% | |
| 11/12/2021 | Geode Capital Management LLC | 617,827 | $4.47M | 0.0% | +6.0% | 1.456% | |
| 11/10/2021 | Goldman Sachs Group Inc. | 117,656 | $0.85M | 0.0% | -43.6% | 0.277% | |
| 11/10/2021 | Citigroup Inc. | 6,773 | $49K | 0.0% | -88.6% | 0.016% | |
Data available starting January 2016
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Read More on Neoleukin Therapeutics
Today's Range
Now: $18.49
52 Week Range
Now: $18.49
Volume
90,936 shs
Average Volume
50,104 shs
Market Capitalization
$173.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.11
